Mirviss Jeffrey B.

Mirviss Jeffrey B., an executive vice president and president of peripheral interventions at Boston Scientific, has been a consistent seller of the company’s stock over the past two years, with no open-market purchases recorded in his SEC Form 4 filings. Across 43 transactions spanning two companies, his total sell value reached approximately $11.49 million, entirely in Boston Scientific (BSX) shares. The most recent cluster of sales occurred in February 2025, including a $1.37 million disposition on February 12, followed by smaller sales on February 19 ($159,078), February 24 ($487,369), and February 25 ($279,552). Earlier, he sold $642,658 in January 2025 and $4.79 million in May 2024, alongside a $963,930 sale in March 2024 and a $329,096 sale in February 2024. The pattern is heavily skewed toward selling, but the filings also reveal a significant mechanical component. Many of the transactions are coded as “M” (option exercises) paired with “F” (shares withheld for tax), which generate no cash proceeds and are automatic rather than discretionary. For instance, in mid-February 2025, Mirviss exercised options on February 14, 16, and 17, with corresponding tax-withholding sales of $134,335, $143,779, and $161,393. The larger open-market sales, however, represent deliberate reductions of his BSX stake. He also received equity grants (coded “A”) in February 2025 and July 2026, though these carry no dollar value and are compensation rather than conviction buys. Notably, all recent activity is confined to BSX; the only other company in his filing history, CNMD, appears solely as a zero-value grant in July 2026, indicating no trading position there.